HOME > MARKETS > MARKET COMMENTARY
  MARKET COMMENTARY
EQUITY
Shilpa Medicare informs about initiation of NCLT order on FTF Pharma
Sep-10-2026
Pursuant to Regulation 30 of Listing Regulations, Shilpa Medicare has informed that the Hon’ble National Company Law Tribunal, Ahmedabad Bench -Court II, vide its order pronounced on September 9, 2026 in CP (IB) No. 346 (AHM) 2025, has admitted the application filed under Section 9 of the Insolvency and Bankruptcy Code, 2016 (IBC) by Immacule Lifesciences against FTF Pharma, a Wholly Owned Subsidiary of Shilpa Medicare, and has ordered commencement of the Corporate Insolvency Resolution Process (“CIRP”) against FTF Pharma. The Company is in discussions with its legal advisors to evaluate the overall legal position and the future course of action for the same. We will provide requisite updates at appropriate time on any further development on the matter. A copy of the order of the Hon’ble NCLT dated September 9, 2026 is enclosed for information and records. The requisite details as prescribed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025- CFDPOD2/I/3762/2026 dated January 30, 2026, are enclosed as Annexure A.

The above information is a part of company’s filings submitted to BSE.
  RELATED NEWS >>